Herbalife(US:HLF)2026-02-18 21:23Financial Performance - Net sales for the year ended December 31, 2025, were $5,037.5 million, an increase of $44.4 million, or 0.9%, compared to 2024[285]. - Net income attributable to Herbalife for 2025 was $228.3 million, or $2.20 per diluted share, a decrease of $26.0 million, or 10.2%, from 2024[286]. - The Primary Reporting Segment reported net sales of $4,758.4 million for 2025, an increase of $62.9 million, or 1.3%, compared to 2024[290]. - Contribution margin for the Primary Reporting Segment was $2,037.2 million, or 42.8% of net sales, an increase of $32.9 million, or 1.6%, from 2024[293]. - The 0.9% increase in net sales for 2025 was primarily driven by a 3.2% favorable impact of price increases, offset by a 1.6% unfavorable impact from foreign currency fluctuations and a 0.5% decrease in sales volume[285]. - Gross profit was $3,922.9 million for the year ended December 31, 2025, maintaining a gross profit margin of 77.9%[314]. - Gross profit as a percentage of net sales was flat for the year ended December 31, 2025, compared to 2024, with a favorable impact of price increases of 78 basis points and other cost changes of 9 basis points, offset by unfavorable impacts from foreign currency fluctuations of 65 basis points and higher inventory write-downs of 10 basis points[315]. Regional Sales Performance - North America reported net sales of $1,033.0 million for the year ended December 31, 2025, a decrease of $21.4 million, or 2.0%, compared to 2024[296]. - Latin America achieved net sales of $881.2 million for the year ended December 31, 2025, an increase of $48.7 million, or 5.8%, compared to 2024[300]. - EMEA region net sales were $1,114.4 million for the year ended December 31, 2025, reflecting an increase of $29.6 million, or 2.7%, compared to 2024[304]. - Asia Pacific region, excluding China, reported net sales of $1,729.8 million for the year ended December 31, 2025, an increase of $6.0 million, or 0.3%, compared to 2024[307]. - China region net sales were $279.1 million for the year ended December 31, 2025, a decrease of $18.5 million, or 6.2%, compared to 2024[311]. - In India, net sales increased by $44.8 million, or 5.3%, for the year ended December 31, 2025, supported by a reduction in GST rates[308]. Cost Management and Expenses - Selling expenses were $1,782.4 million for the year ended December 31, 2025, representing 35.4% of net sales, a decrease from 35.7% in 2024, primarily due to favorable changes in the mix of products and countries[317][318]. - General and administrative expenses decreased to $1,664.3 million for the year ended December 31, 2025, or 33.0% of net sales, down from 34.6% in 2024, driven by lower labor and benefits costs of $78.3 million[319][320]. - The company continues to assess its cost structure and potential pricing actions in response to ongoing inflationary pressures[284]. Strategic Initiatives - The company’s strategies focus on improving daily consumption approaches and leveraging technology to enhance Member experiences and drive sales[280]. - The company launched new products including a healthy lifespan supplement and MultiBurn, aimed at enhancing member sales capabilities[298]. - The beta version of the Pro2col health and wellness digital platform was unveiled in July 2025, with a successful release in December 2025[299]. Cash Flow and Capital Expenditures - Operating cash flow increased to $333.3 million for the year ended December 31, 2025, compared to $285.4 million in 2024, attributed to higher net income and lower income taxes[328]. - Capital expenditures were $80.5 million for the year ended December 31, 2025, down from $112.2 million in 2024, with significant investments in digital technology initiatives[329]. Debt and Financing - The company issued $800.0 million aggregate principal amount of senior secured notes due 2029, with an interest rate of 12.250% per annum payable semiannually[348]. - The 2024 Term Loan B Facility has an aggregate principal amount of $400.0 million and requires quarterly payments equal to 5.0% of the principal amount per annum, starting September 2024[339]. - The company repaid $981.0 million of long-term debt by extinguishing the 2018 Credit Facility, resulting in a loss on extinguishment of approximately $2.5 million[340]. - As of December 31, 2025, the outstanding principal on the 2029 Secured Notes was $800.0 million, and the company had no borrowings outstanding under the 2024 Revolving Credit Facility[348][346]. - The weighted-average interest rate for borrowings under the 2024 Credit Facility was 11.64% as of December 31, 2025, compared to 10.35% as of December 31, 2024[346]. Working Capital and Assets - The company had positive working capital of $131.8 million as of December 31, 2025, an increase of $218.5 million from negative working capital of $86.7 million in 2024[363]. - Cash and cash equivalents held by Herbalife Ltd. and its U.S. entities totaled $47.8 million as of December 31, 2025[357]. - The company had goodwill of approximately $100.5 million, an increase of $12.8 million from $87.7 million in 2024, primarily due to the acquisition of Link BioSciences Inc.[377]. - The company had marketing-related intangible assets of approximately $310.0 million as of December 31, 2025, with no impairment recorded during the years ended December 31, 2025, and 2024[377]. Tax and Accounting - The company believes it is more likely than not that the net carrying value of deferred income tax assets will be realized, although realization is not assured[380]. - The company initiated changes to its corporate entity structure, including intra-entity transfers of intellectual property to a European subsidiary, resulting in a step-up in tax basis on the fair value of the intellectual property[380]. - Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the position will be sustained upon examination by taxing authorities[381]. - The company accounts for foreign currency transactions in accordance with FASB ASC Topic 830, with foreign subsidiaries' asset and liability accounts translated into U.S. dollars at period-end exchange rates[383].